Dimitrios N. Kiortsis
BACKGROUND AND OBJECTIVE: Very few drugs are approved for obesity treatment by regulatory agencies. Very recently phentermine/topiramate controlled-release [PHEN/TPM CR; (Qsymia®)] obtained Food and Drug Administration (FDA) approval as an addition to a reduced-calorie diet and exercise …
Ekaterini Koiou, Konstantinos Tziomalos, Ilias Katsikis, Dimitrios Delkos, Elena A. Tsourdi, Dimitrios Panidis
OBJECTIVE: Polycystic ovary syndrome (PCOS) is characterized by obesity and insulin resistance (IR), which result in elevated plasminogen activator inhibitor-1 (PAI-1) levels. We aimed to assess the changes in PAI-1 levels in PCOS during treatment with metformin and during weight loss …
Christos G. Verras, Georgios A. Christou, Yannis V. Simos, George D. Ayiomamitis, Andreas J. Melidonis, Dimitrios N. Kiortsis
OBJECTIVE: The elucidation of the changes of fetuin-A in the context of bariatric surgery. DESIGN: Twenty obese patients (8 males, 12 females; body mass index = 42.5±3.4 kg/m2) were studied at baseline and 6 months after bariatric surgery. RESULTS: Serum fetuin-A levels did not differ with regard to the presence …